i3 (Ann Arbor, Michigan) Expands Partnership with Eli Lilly and Company
Published: Sep 16, 2010
This agreement builds on i3’s steady growth in the area of functional service provision (FSP), having composed and deployed successful FSP teams throughout the industry since 1999.
Life science companies have found that partnering with service providers in functional areas, such as information sciences—including data management, medical writing, and biostatistical services—enhances efficiencies, improves quality, and reduces costs. These benefits are critical to companies that need to compete in a dynamic business environment while retaining the capabilities of employees who know their systems and culture.
“i3, with an established presence on the north side of Indianapolis, has proved itself as a partner capable of consistently delivering high-quality work within our agreed-upon performance metrics,” said Aarti Shah, Ph.D., vice president statistics and advanced analytics hub, Eli Lilly and Company.
“The continued expansion of the relationship between Lilly and i3 is another step in the evolution of the successful strategic partnership we share,” said Gregg Dearhammer, group president, i3 Statprobe and i3 Drug Safety. “Over the last four years, our teams have built something truly novel and innovative—a true strategic alliance. This latest addition to our alliance is evidence that emphasis on quality, customer service, efficiency, and ability to deliver are highly valued by our partners like Lilly and critical to their ability to meet their goals.”
About i3 Statprobe
i3 Statprobe provides clinical data services to pharmaceutical, biologic, medical device and diagnostics customers. It is a leader in the development and growth of functional alliances and strategic partnerships, which help enhance efficiencies and reduce costs in clinical trials.
i3 takes a 360-degree view of healthcare to help its global pharmaceutical, biotechnology, and medical device customers bring safe and effective products to market quickly and help demonstrate their value, leading to increased ROI and better patient care. i3’s integrated businesses combine a deep understanding of data and methodologies; therapeutic, scientific, and functional proficiency; and the expertise to help design research that demonstrates a product’s value, and helps achieve market access and assure reimbursement. More information about i3 can be obtained at www.i3global.com.
Jodie Klein Klein OnPoint (703) 528-3333 (703) 528-7577 (fax) (703) 801-7955 (cell)